{
    "clinical_study": {
        "@rank": "9861", 
        "acronym": "ORT-OXI-2009", 
        "arm_group": [
            {
                "arm_group_label": "Pentoxifylline + Tocopherol", 
                "arm_group_type": "Active Comparator", 
                "description": "Pentoxifylline 800 mg/day (400 mg/12hours)  + Tocopherol 1000 mg/day   oral during 6 months"
            }, 
            {
                "arm_group_label": "pentoxifylline + tocopherol + Hyperbaric Oxygen Therapy", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The pentoxifylline used with tocopherol achieves a certain effectiveness in the treatment of\n      the fibrosis.\n\n      Hyperbaric oxygen therapy has been recommended and used in a wide variety of medical\n      conditions including the treatment of delayed radiation injuries (soft tissue and bony\n      radiation necrosis). The hyperbaric oxygen therapy increases the formation of granulation\n      tissue and produces angiogenesis maintained after use."
        }, 
        "brief_title": "Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Fibrosis", 
        "condition_browse": {
            "mesh_term": "Fibrosis"
        }, 
        "detailed_description": {
            "textblock": "Patients with head and neck tumors often present superficial radiation induced fibrosis and\n      other late complications of radiotherapy that can seriously affect their quality of life.\n\n      The pentoxifylline used with tocopherol achieves a certain effectiveness in the treatment of\n      the fibrosis.\n\n      Hyperbaric oxygen therapy has been recommended and used in a wide variety of medical\n      conditions including the treatment of delayed radiation injuries (soft tissue and bony\n      radiation necrosis). The hyperbaric oxygen therapy increases the formation of granulation\n      tissue and produces angiogenesis maintained after use.\n\n      Both treatments in combination could produce a synergistic effect because the angiogenesis\n      induced by hyperbaric oxygen therapy allow better access to drugs to the injury. The\n      magnetic resonance, provides data of the fibrosis and other side effects of radiotherapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Over 18 years and under 70 years old.\n\n          2. Patients who have received radiotherapy after being diagnosed with cancer of upper\n             aerodigestive tract, and have skin toxicity grade II or higher.\n\n          3. Follow-up for at least a year after the radiation treatment is completed.\n\n          4. Absence of tumor at the time of recruitment.\n\n          5. Patients with the capacity to give informed consent\n\n        Exclusion Criteria:\n\n          1. Allergy or hypersensitivity to Pentoxifylline or others xanthines, or to  Tocopherol\n             (vitamin E).\n\n          2. Patients taking oral anticoagulants (acenocoumarol, warfarin).\n\n          3. Known hemorrhagic/coagulation disorder.\n\n          4. Vitamin K deficiency due to any cause.\n\n          5. Use of estrogens oral contraceptives.\n\n          6. Serious bleeding or extensive retinal hemorrhage.\n\n          7. Ischaemic heart diseases, including recent Myocardial Infarction.\n\n          8. Serious cardiac arrhythmia.\n\n          9. Severe liver disease.\n\n         10. Severe renal failure (creatinine clearance <30 mL/min).\n\n         11. Hypotension.\n\n         12. Patients with metal objects or electronic devices such as cardiac pacemakers,\n             artificial heart valves or cochlear implants, or any other contraindication for MRI\n\n         13. Contraindication for Hyperbaric oxygen therapy.\n\n         14. Patients with mobility problems.\n\n         15. Female patients who are pregnant or lactating\n\n         16. Any other situation or condition that, in the opinion of the investigator, may\n             interfere with optimal participation in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01822405", 
            "org_study_id": "ORT-OXI-2009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pentoxifylline + Tocopherol", 
                "description": "Pentoxifylline 800 mg/day (400 mg/12hours)  + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months", 
                "intervention_name": "pentoxifylline with tocopherol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "pentoxifylline + tocopherol + Hyperbaric Oxygen Therapy", 
                "description": "pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.\nHyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment.", 
                "intervention_name": "pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pentoxifylline", 
                "Tocopherols", 
                "Vitamin E", 
                "Alpha-Tocopherol", 
                "Tocotrienols"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 27, 2013", 
        "location": {
            "contact": {
                "email": "coton@ull.es", 
                "last_name": "Claudio Ot\u00f3n, MD"
            }, 
            "facility": {
                "address": {
                    "city": "La Laguna", 
                    "country": "Spain", 
                    "state": "S/C de Tenerife", 
                    "zip": "38320"
                }, 
                "name": "Hospital Universitario de Canarias"
            }, 
            "investigator": {
                "last_name": "Claudio Ot\u00f3n, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen", 
        "overall_contact": {
            "email": "coton@ull.es", 
            "last_name": "Claudio Ot\u00f3n, MD"
        }, 
        "overall_official": {
            "affiliation": "Hospital Universitario de Canarias", 
            "last_name": "Claudio Ot\u00f3n, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Spain: Spanish Agency of Medicines"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change is calculated as the latest time point (6 months) minus the earliest time point (baseline)", 
            "measure": "Change in skin fibrosis measured by MRI", 
            "safety_issue": "Yes", 
            "time_frame": "From baseline to 6 month of starting treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01822405"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change is calculated as the latest time point (6 months) minus the earliest time point (baseline)", 
            "measure": "Clinical assessment of the radiation late (delayed) toxicity for mucosal membranes, salivary glands, larynx and skin by the LENT-SOMA scale (Late Effect Normal Tissue Task Force / Subjective, Objective, Management, Analytic scale)", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline and 6 months"
        }, 
        "source": "Hospital Universitario de Canarias", 
        "sponsors": {
            "collaborator": {
                "agency": "Instituto M\u00e9dico Tinerfe\u00f1o IMETISA", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hospital Universitario de Canarias", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}